A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel?) in healthy young women administered twice daily for 14 days
Product/Publication Type(s):
Peer-reviewed publications in scholarly journals Published/In Press
Target Audience:
Professionals, Policymakers, Students
To Obtain Copies (URL or Email):
COVID-19 Related Data:
N/A